Month: September 2026

TORONTO, Sept. 30, 2026 (GLOBE NEWSWIRE) — Xanadu Quantum Technologies Limited (“Xanadu”; NASDAQ/TSX: XNDU), a leading photonic quantum computing company, today announced that Rafal Janik, Xanadu’s Chief Operating Officer, has entered into an automatic securities disposition plan (the “Plan”) to sell Class B Subordinate Voting Shares of Xanadu (“Class B Shares”) held directly by Mr. Janik. The Plan has been adopted in accordance with applicable securities laws and Xanadu’s internal policies. Sales of Class B Shares under the Plan are eligible to commence on or after December 29, 2026.

The Plan was entered into when Mr. Janik was not in possession of material non-public information regarding Xanadu and permits trades to be made in accordance with pre-arranged instructions given when Mr. Janik is not in possession of material non-public information regarding Xanadu. The Plan provides for the sale of up to 312,914 Class B Shares and will terminate no later than December 31, 2027. The Class B Shares that could potentially be disposed of under the Plan may include Class B Shares, currently held, directly or indirectly, by Mr. Janik and Class B Shares issued to Mr. Janik upon vesting and/or exercise of options and restricted share units granted to Mr. Janik as compensation for his services as Chief Operating Officer. Sales of Class B Shares under the Plan will be effected by an independent securities broker in accordance with the trading parameters, price and other restrictions and instructions set out in the Plan. The Plan has been authorized and established in the form approved by Xanadu and contains meaningful restrictions on the ability of Mr. Janik to modify, suspend or terminate the Plan.

This announcement is made and will be available on SEDAR+ at www.sedarplus.ca pursuant to the recommended practices set forth in Staff Notice 55-317 Automatic Securities Disposition Plans of the Canadian Securities Administrators. Information regarding the Plan and transactions thereunder, as the case may be, may be accessed on SEDI at www.sedi.ca.

About Xanadu

Founded in 2016, Xanadu is a Canadian photonic quantum computing company with the mission to build quantum computers that are useful and available to people everywhere. Xanadu is building fault-tolerant quantum computers using light, with systems designed to compute at room temperature. Xanadu develops both hardware and software, including PennyLane, its open-source quantum computing platform. Xanadu is the first pure-play photonic quantum computing company to list on public markets (Nasdaq/TSX: XNDU) and is recognized globally for its breakthroughs in scalable quantum technologies. Visit xanadu.ai or follow on X @XanaduAI.

Contacts

Press Contact:press@xanadu.ai
Investor Relations:investors@xanadu.ai

Not for distribution to U.S. news wire services or for dissemination in the United States

Toronto, Ontario, Sept. 30, 2026 (GLOBE NEWSWIRE) — Avante Corp. (TSX.V: XX) (“Avante” or the “Company”) is pleased to announce that the Company’s five nominees set forth in the Company’s management information circular dated August 25, 2026 (the “Circular”), being Daniel Argiros, Wendy Teramoto, Robert Klopot, Emmanuel Mounouchos and Jonathan Pollack, were all elected as directors of the Company at the annual general and special meeting of shareholders held today (the “Meeting”). Each of the directors elected at the Meeting will hold office until the next annual general meeting of the Company or until their successor is duly elected or appointed, unless their post is vacated earlier.

At the Meeting, shareholders also approved the appointment of Deloitte LLP as the auditor of the Company until the close of the next annual general meeting, as well as the ratification of the Company’s stock option plan. Shareholders did not approve any of Shareholder Proposal One, Shareholder Proposal Two, Shareholder Proposal Three, Shareholder Proposal Four or Shareholder Proposal Five, each as described in Schedule D of the Circular.

Further information with respect to the matters considered at the Meeting can be found in the Circular, which is available under Avante’s issuer profile on SEDAR+ at www.sedarplus.ca.

Detailed voting results with respect to the matters considered at the Meeting are set out in the tables below.

Election of Directors

Nominee	Votes For	% of Votes For	Votes Withheld	% of Votes Withheld
Daniel Argiros	12,877,690	60.0%	8,586,436	40.0%
Wendy Teramoto	12,877,690	60.0%	8,586,436	40.0%
Robert Klopot	12,877,690	60.0%	8,586,436	40.0%
Emmanuel Mounouchos	12,779,290	59.5%	8,684,836	40.5%
Jonathan Pollack	20,918,935	97.5%	545,191	2.5%

Appointment of Auditor

Votes For	% of Votes For	Votes Withheld	% of Votes Withheld
14,226,030	66.1%	7,308,318	33.9%

Ratification of Stock Option Plan

Votes For	% of Votes For	Votes Against	% of Votes Against
12,747,290	59.4%	8,716,836	40.6%

Shareholder Proposals

Proposal	Votes For	% of Votes For	Votes Against	% of Votes Against
Shareholder Proposal One	9,776,876	45.5%	11,687,250	54.5%
Shareholder Proposal Two	9,776,876	45.5%	11,687,250	54.5%
Shareholder Proposal Three	9,136,613	42.6%	12,327,513	57.4%
Shareholder Proposal Four	9,136,613	42.6%	12,327,513	57.4%
Shareholder Proposal Five	9,136,613	42.6%	12,327,513	57.4%

Emmanuel Mounouchos, Founder, Chief Executive Officer and Board Chair of Avante, commented, “Thank you to our shareholders for their continued support. We look forward to welcoming you to next year’s annual meeting, which will be held both in person and online, where you can meet our leadership, see our technology in action and have your questions answered directly.”

About Avante Corp.

Avante Corp. is a Toronto-based leading provider of security personnel and technology-enabled security solutions for residential and commercial clients. Avante’s mission is to deliver an elevated level of security globally, with a white-glove approach for high-net-worth families and corporations alike, through advanced solutions and methods for detecting conditions requiring immediate response. The Company has developed a diversified security platform that leverages cutting-edge technology to deliver superior security services. With an experienced team and a proven track record of solid growth, Avante is taking steps to build a broad portfolio of security businesses and solutions for its customers through organic growth complemented by strategic acquisitions. Avante acquires, manages, and develops industry-leading companies that provide specialized, mission-critical solutions to address the security risks faced by its clients. Avante is listed on the TSX Venture Exchange under the ticker “XX”. For more information, please visit www.avantecorp.ca and consider joining our investor email list.

Forward-Looking Statements

This news release may contain “Forward-Looking Information” as defined by applicable Canadian securities laws. Forward-Looking Information is based on various estimates and assumptions that, while deemed reasonable by management, are inherently subject to significant business, economic, and competitive uncertainties and contingencies. Forward-Looking Information is typically identified by the use of forward-looking words such as “may,” “should,” “will,” “could,” “intend,” “estimate,” “plan,” “anticipate,” “expect,” “believe,” or “continue,” along with the negative forms or similar terms, and includes statements in this press release related to Avante’s next annual meeting of shareholders. These involve known and unknown risks, uncertainties, and factors that could cause actual results, performance, or achievements to differ materially from the estimated or implied results, performance, or achievements described or forecasted in such information. Such statements are not guarantees of future performance. Avante’s comments expressed or implied by Forward-Looking Information are subject to numerous risks, uncertainties, and conditions, many of which are beyond Avante’s control, and undue reliance should not be placed on them. Forward-Looking Information is entirely qualified by inherent risks and uncertainties, including adverse market conditions impacting results; the possibility of future results differing from historical performance; market competition affecting business, results, and financial condition; and other risk factors listed in documents filed by Avante on its profile on SEDAR+ at www.sedarplus.ca, including its annual Management’s Discussion and Analysis. Except as required by applicable securities laws, Avante does not undertake any obligation to update or revise any Forward-Looking Information, whether due to new information, events, or otherwise.

Avante Corp.

For further information:
Emmanuel Mounouchos
CEO, Chairman, and Founder
(416) 923-6984
manny@avantesecurity.com

Pardeep Sangha
Investor Relations
(604) 572-6392
pardeep@angadcapital.com

Neither the TSX Venture Exchange Inc. (“Exchange”) nor its regulation services provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Oculis Announces Resignation of Lionel Carnot from Board of Directors

ZUG, Switzerland, September 30, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announces that director Lionel Carnot will be resigning from the Board of Directors, effective today, after nearly a decade of dedicated service since 2017.

Anthony Rosenberg, Chair of the Board, remarked: “On behalf of the Board and the entire Oculis team, we wish to extend our sincere gratitude to Lionel for his invaluable service, leadership and guidance over nearly a decade, covering a transformative period for Oculis, where it evolved from a private startup company to a publicly listed late-stage biopharmaceutical company. His contributions to the Board and Oculis have been instrumental in our growth and evolution to become an emerging leader in neuro-ophthalmology.”

Lionel Carnot remarked: “It has been a privilege to work alongside Oculis’ talented and dedicated team committed to addressing significant unmet medical needs and advance innovative solutions for patients suffering from ophthalmic and neuro-ophthalmic diseases. As the Company enters its next stage of growth, this is a timely point for me to step down and focus on other commitments. As an investor, I remain confident in the potential of Oculis’ pipeline and look forward to the Company achieving important milestones in the years ahead.”

Mr. Carnot’s departure is purely a personal decision and is not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices. Following the resignation, the Board will consist of eight members and the Remuneration Committee, of which Mr. Lionel served as chair, will consist of Geraldine O’Keeffe as chair and Gregory Perry and Robert Warner as members. Pursuant to Swiss law, the vacancy on the Board resulting from Mr. Carnot’s resignation may only be filled at a future annual or special general meeting. Oculis will begin identifying a successor for Mr. Carnot and will provide updates as appropriate.

-ENDS-

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neuro-axonal diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial, and is being developed with a genotype-based approach for treating patients with dry eye disease (DED). Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
        
For more information, please visit: www.oculis.com

Oculis Contact
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com

Media Relations
ICR Healthcare
Amber Fennell
oculis@icrhealthcare.com